CTNS molecular genetics profile in a Persian nephropathic cystinosis population

Farideh Ghazi1, Rozita Hosseini2, Mansoureh Akouchekian1

  • 1Department of Medical Genetics and Molecular Biology, Faculty of Medicine, Iran University of Medical Sciences (IUMS), Tehran, Iran.

Insights

This study identified eight novel and eight previously reported CTNS gene mutations in 28 Iranian nephropathic cystinosis patients. The findings offer guidance for molecular diagnostics of cystinosis in Iran.

Area of Science:

  • Genetics
  • Molecular Biology
  • Pediatric Nephrology

Background:

  • Nephropathic cystinosis is a rare genetic disorder characterized by lysosomal accumulation of cystine.
  • Early diagnosis and molecular characterization are crucial for effective management and genetic counseling.

Purpose of the Study:

  • To investigate the spectrum of CTNS gene mutations in 28 Iranian patients with nephropathic cystinosis.
  • To identify novel mutations and characterize the mutational profile in this cohort.

Main Methods:

  • Molecular analysis involved polymerase chain reaction (PCR) amplification and direct sequencing of CTNS coding exons.
  • The presence or absence of the common 57-kb founder deletion was assessed.

Main Results:

  • The common 57-kb deletion was absent in all patients.
  • Mutations were identified in exons 6 and 7 (50% of patients), with five novel homozygous deletions in exon 6.
  • Eight previously reported and eight novel mutations were identified, including frame-shift and splice site mutations.

Conclusions:

  • This study provides the first molecular genetic analysis of non-ethnic-specific Iranian nephropathic cystinosis patients.
  • The identified mutations expand the known spectrum of CTNS variants.
  • Findings may guide molecular diagnostics for cystinosis in the Iranian population.
Abstract

Related Concept Videos

Cystic Fibrosis: Pathogenesis01:23

Cystic Fibrosis: Pathogenesis

Cystic fibrosis (CF), an autosomal recessive disorder, significantly affects the function of exocrine glands. This genetically inherited disease is characterized by the production of thick and sticky mucus, which can severely affect various organs and systems in the body.
CF is primarily caused by a genetic mutation in a chromosome 7 gene coding for the cystic fibrosis transmembrane conductance regulator (CFTR) protein. The most common gene mutation leading to CF is the ΔF508 mutation,...
966
Pharmacogenetics of Phase I Enzymes: Cytochrome P450 Isozymes01:28

Pharmacogenetics of Phase I Enzymes: Cytochrome P450 Isozymes

Cytochrome P450 (CYP450) enzymes are a superfamily of heme-containing monooxygenases that play a pivotal role in Phase I drug metabolism by catalyzing oxidation and reduction reactions.These enzymes transform lipophilic xenobiotics into more hydrophilic metabolites, facilitating subsequent Phase II conjugation and eventual excretion. The CYP450 family is classified into families (e.g., CYP1–CYP3) and subfamilies (e.g., CYP2A, CYP2C), based on amino acid sequence homology.CYP450...
70
Principles of Pharmacogenetics: Types of Genetic Variants01:27

Principles of Pharmacogenetics: Types of Genetic Variants

The human genome is over 99.9% identical between individuals, yet genetic differences exist at millions of bases. The human genome contains approximately 3 million variant positions per individual, many of which are heterozygous, contributing to genetic diversity and individual traits. Genetic variations include single-nucleotide polymorphisms (SNPs), insertions, deletions, and copy number variations (CNVs).SNPs, the most common variation, involve single-base changes in DNA. These can be...
65
Pharmacogenomics: Identification of New Drug Targets01:29

Pharmacogenomics: Identification of New Drug Targets

Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
55
Pharmacogenetics of Drug Transporters: P-Glycoprotein and Solute Carrier Transporters01:16

Pharmacogenetics of Drug Transporters: P-Glycoprotein and Solute Carrier Transporters

The pharmacogenetics of drug transporters is increasingly recognized as a critical factor influencing interindividual variability in drug absorption, distribution, and elimination. These membrane-bound proteins regulate drugs' movement across cellular barriers by actively pumping them out (efflux) or facilitating their uptake (influx). Among the major transporter families, ATP-binding cassette (ABC) and solute carrier (SLC) transporters play particularly prominent roles. Genetic polymorphisms...
83
Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu01:29

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu

Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
76